Status:
COMPLETED
Change of Gut Microbiome in the Treatment of Graves' Disease
Lead Sponsor:
Seoul St. Mary's Hospital
Conditions:
Graves' Disease
Eligibility:
All Genders
19-69 years
Brief Summary
Graves' disease is the main cause of hyperthyroidism. Graves' disease has a prevalence of 0.5% in the general population. As a non-surgical treatment, antithyroid drug (ATD) and radioactive iodine tre...
Eligibility Criteria
Inclusion
- More than 19 years and lesser than 70 years
- First diagnosed as Graves' disease and planned to have antithyroid drug
Exclusion
- Pregnancy and lactating women
- Inflammatory bowel disease
- Active malignancy
- Autoimmune disease
- Immune-deficiency patients
Key Trial Info
Start Date :
May 19 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04383795
Start Date
May 19 2020
End Date
December 31 2021
Last Update
August 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul St. Mary hospital
Seoul, South Korea